Physician profile
Jonathan D Graf
NPI 1487660635
$22,690.59
in general payments reported to CMS, 2019-2025
11 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,200 · 2021: $4,935 · 2022: $28.23 · 2023: $213 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.45 |
| Education | $153.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,600.53 | 2019-2021 | |
| Gilead Sciences, INC. | $3,500.00 | 2019 | |
| Eli Lilly and Company | $125.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $124.94 | 2019 | |
| Janssen Biotech, INC. | $121.61 | 2021-2025 | Tremfya |
| Genentech, INC. | $53.45 | 2025 | |
| Ucb, INC. | $48.38 | 2019 | |
| Lilly USA, LLC | $46.51 | 2023 | Taltz |
| Amgen INC. | $41.94 | 2023 | Tavneos |
| Genentech USA, INC. | $28.23 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Graf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.